2,6-二甲氧基吡啶广泛应用于多种药物分子中,包括酶抑制剂/激动剂、抗艾滋药物、抗菌药和麻醉剂等。
制备将乙酸钯(Pd(OAc)₂)(0.023 mmol,1 mol%)、双吡唑基膦配体(0.047 mmol,2 mol%)加入到干燥的压力管中(10 mL)。随后向反应混合物中依次加入碳酸铯(Cs₂CO₃)(3.50 mmol,1.5 当量)、甲苯(2 mL)、2,6-二溴吡啶(2.34 mmol)和甲醇(2 mL)。将反应体系在80℃下搅拌过夜(24小时),然后冷却至室温。用乙酸乙酯(EtOAc,5 mL)稀释反应混合物,并通过硅藻土垫过滤。浓缩粗产物后,采用快速色谱法纯化,最终得到2,6-二甲氧基吡啶。
中文名称 | 英文名称 | CAS号 | 化学式 | 分子量 |
---|---|---|---|---|
—— | 2,6-dimethoxypyridine N-oxide | 7259-54-3 | C7H9NO3 | 155.153 |
2,6-二羟基吡啶 | 2-hydroxy-6-pyridone | 626-06-2 | C5H5NO2 | 111.1 |
3-羟基-2,6-二甲氧基吡啶 | 2,6-dimethoxypyridin-3-ol | 885963-28-0 | C7H9NO3 | 155.153 |
—— | 3-iodo-2,6-dimethoxypyridine | 214360-56-2 | C7H8INO2 | 265.051 |
—— | 3-deutero-2,6-dimethoxypyridine | 1356156-14-3 | C7H9NO2 | 140.146 |
3-溴-2,6-二甲氧基吡啶 | 3-bromo-2,6-dimethoxypyridine | 13445-16-4 | C7H8BrNO2 | 218.05 |
3-氨基-2,6-二甲氧基吡啶 | 2,6-dimethoxy-3-aminopyridine | 28020-37-3 | C7H10N2O2 | 154.169 |
3,5-二溴-2,6-二甲氧基吡啶 | 3,5-dibromo-2,6-dimethoxypyridine | 16727-44-9 | C7H7Br2NO2 | 296.946 |
Bedaquiline is a novel drug approved in 2012 by the FDA for treatment of drug-resistant tuberculosis (TB). Although it shows high efficacy towards drug-resistant forms of TB, its use has been limited by the potential for significant side effects. In particular, bedaquiline is a very lipophilic compound with an associated long terminal half-life and shows potent inhibition of the cardiac potassium hERG channel, resulting in QTc interval prolongation in humans that may result in cardiac arrhythmia. To address these issues, we carried out a drug discovery programme to develop an improved second generation analogue of bedaquiline. From this medicinal chemistry program, a candidate (TBAJ-876) has been selected to undergo further preclinical evaluation. During this evaluation, three major metabolites arising from TBAJ-876 were observed in several preclinical animal models. We report here our synthetic efforts to unequivocally structurally characterize these three metabolites through their independent directed synthesis.